Latest revenue
$1.4M
as of 2026-01-31
Latest net income
$-852.0K
as of 2026-01-31
Net margin
-58.9%
as of 2026-01-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $15.4M
- Enterprise value
- $15.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.99
- 52-wk low
- $1.20
- Beta
- —
- Shares out
- 7.8M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company has a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly matrix. The Company’s principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. ZEO also manufactures Patient Pure X™ (“PPX™”), a proprietary autologous…
AI summary unavailable — showing raw filing excerpt
Generated from ZEOX's filing dated 2026-01-29
Key risks
Item 1A. Risk Factors. This Annual Report contains certain statements relating to future events or the future financial performance of our Company. Prospective investors are cautioned that such statements are only predictions and involve risks and uncertainties, and that actual events or results may differ materially. In evaluating such statements, prospective investors should specifically consider the various factors identified in this Annual Report, including the matters set forth below, which could cause actual results to differ materially from those indicated by such forward-looking statements. If any of the following or other risks materialize, the Company’s business, financial…
AI summary unavailable — showing raw filing excerpt
Generated from ZEOX's filing dated 2026-01-29
Profitability
Gross margin
82.1%
0.4%Operating margin
-103.6%
10.0%Net margin
-106.2%
4.3%Return on equity
388.0%
36.3%Return on assets
-361.6%
26.3%Leverage
Debt / equity
-2.07×
4.0%Long-term debt / equity
-0.01×
109.1%Debt / assets
193.2%
3.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-01-31 | $1.4M | +32.7% | $-852.0K | +31.5% | -58.9% |
Q4 2025 2025-10-31 | $1.7M | +33.0% | $-815.0K | +35.0% | -49.3% |
Q3 2025 2025-07-31 | $1.3M | +19.7% | $-2.1M | -104.7% | -158.7% |
Q2 2025 2025-04-30 | $1.1M | +1.6% | $-1.4M | +0.6% | -121.1% |
Q1 2025 2025-01-31 | $1.1M | -5.5% | $-1.2M | -19.5% | -114.0% |
Q4 2024 2024-10-31 | $1.2M | — | $-1.3M | — | -100.8% |
Q3 2024 2024-07-31 | $1.1M | -10.6% | $-1.0M | +37.4% | -92.8% |
Q2 2024 2024-04-30 | $1.1M | — | $-1.4M | — | -123.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ZEOX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$43.9K
Insider selling
$0
Net activity
+$43.9K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ZEOX
No institutional holdings on file for ZEOX yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once ZEOX's latest filing finishes processing.